



Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 415072002300

Application Number 10/713,248

Applicant

Jennie P. MATHER et al.

Filing Date November 13, 2003

Group Art Unit Not Yet Assigned

Mailing Date February 23, 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
ALH	1.	06/30/1987	4,676,980	Segal et al.			
	2.	03/28/1989	4,816,567	Cabilly et al.			
	3.	09/03/1996	5,552,391	Coutts et al.			
	4.	10/15/1996	5,565,332	Hoogenboom et al.			
	5.	12/03/1996	5,580,717	Dower et al.			
	6.	08/12/1997	5,656,444	Webb et al.			
	7.	09/09/1997	5,665,570	Yamagata et al.			
	8.	10/14/1997	5,677,425	Bodmer et al.			
	9.	03/31/1998	5,733,743	Johnson et al.			
	10.	06/02/1998	5,760,185	Kimachi et al.			
	11.	06/30/1998	5,773,247	Maeda et al.			
	12.	09/15/1998	5,807,715	Morrison et al.			
	13.	02/02/1999	5,866,692	Shitara et al.			
	14.	07/27/1999	5,929,212	Jolliffe et al.			
	15.	08/03/1999	5,932,225	Wallach et al.			
	16.	12/07/1999	5,997,867	Waldmann et al.			
	17.	04/25/2000	6,054,297	Carter et al.			
	18.	04/25/2000	6,054,561	Ring			
	19.	08/29/2000	6,110,724	Nakagomi et al.			
	20.	09/12/2000	6,117,653	Thoma			
	21.	01/30/2001	6,180,377	Morgan et al.			
	22.	04/04/2001	6,221,644	Berka et al.			
	23.	07/24/2001	6,265,150	Terstappen et al.			
	24.	12/18/2001	6,331,415	Cabilly et al.			
	25.	06/18/2002	6,406,840	Li et al.			
	26.	07/09/2002	6,416,999	Li et al.			

EXAMINER:

/Anne Holleran/ (06/22/2003) CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket Number 415072002300		Application Number 10713,248	
	Applicant Jennie P. MATHER et al.			
	Filing Date November 13, 2003		Group Art Unit Not Yet Assigned	
	Mailing Date February 23, 2004			

alsh / Anne Holleran / 06/22/2004 / Chari et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Country	Class	Subclass	Translation YES NO
alsh	28	12/23/92	Europe			


OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
ALH	29.	Aruffo, A. et al. (1987). "Molecular Cloning of a CD 28 cDNA by a High-Efficiency COS Cell Expression System," <i>Proc. Natl. Acad. Sci USA</i> 84:8573-8577.
	30.	Bird, R. E. et al. (1988). "Single-Chain Antigen-Binding Proteins," <i>Science</i> 242:423-426.
	31.	Brown, B. A. et al. (1987). "Tumor-Specific Genetically Engineered Murine/Human Chimeric Monoclonal Antibody," <i>Cancer Res.</i> 47:3577-3583.
	32.	Carter, P. et al. (1992). "Humanization of an Anti-p185 ^{HER2} Antibody for Human Cancer Therapy," <i>Proc. Nat. Acad. Sci USA</i> 89:4285-4289.
	33.	Co, M. S. et al. (1991). "Humanized Antibodies for Antiviral Therapy," <i>Proc. Nat. Acad. Sci USA</i> 88:2869-2873.
	34.	Co, M. S. et al. (1992). "Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen," <i>J. Immunol.</i> 148(4):1149-1154.
	35.	Coligan, J.E. et al., eds (1991). "Isolation of Proteins Using Antibodies," <i>In Current Protocols in Immunology</i> , John Wiley & Sons, Inc., Volume 2, Supplement 18, pp. 8.2.1-8.2.9.
	36.	Daugherty, B. L. et al. (1991). "Polymerase Chain Reaction Facilitates the Cloning, CDR-grafting, and Rapid Expression of a Murine Monoclonal Antibody Directed Against the CD 18 Component of Leukocyte Integrins," <i>Nucl. Acids Res.</i> 19(9):2471-2476.
	37.	Dillman, R. O. et al. (1988). "Superiority of an Acid-Labile Daunorubicin-Monoclonal Antibody Immunoconjugate Compared to Free Drug," <i>Cancer Research</i> 48:6097-6102.
	38.	Gorman, S. D. et al. (1991). "Reshaping a Therapeutic CD4 Antibody," <i>Proc. Nat. Acad. Sci USA</i> 88:4181-4185.
	39.	Jones, P. T. et al. (1986). "Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse," <i>Nature</i> 321:522-525.
	40.	Kettleborough, C. A. et al. (1991). "Humanization of a Mouse Monoclonal Antibody by CDR-grafting: Importance of Framework Residues on Loop Conformation," <i>Protein Engineering</i> 4(7):773-783.

EXAMINER: /Anne Holleran/ 06/22/2004 DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 415072002300

Application Number 10/713,248

Applicant

Jennie P. MATHER et al.

Filing Date November 13, 2003

Group Art Unit No. 611 Yet Assigned

Mailing Date February 23, 2004

ALH	41.	Kohler, G. et al. (1975). "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," <i>Nature</i> 256:495-497.
	42.	Lobuglio, A. F. et al. (1989). "Mouse/Human Chimeric Monoclonal Antibody in Man: Kinetics and Immune Response," <i>Proc. Natl. Acad. Sci. USA</i> 86:4220-4224.
	43.	Lowe (1979). "An Introduction to Affinity Chromatography," <i>In Laboratory Techniques in Biochemistry and Molecular Biology</i> , North-Holland Publishing Company, Work, T. S. et al., eds., Volume 7 Part II, pp. 269-273 (Table of Contents Only).
	44.	Maeda, H. et al. (1991). "Construction of Reshaped Human Antibodies with HIV-Neutralizing Activity," <i>Human Antibodies Hybridomas</i> 2:124-134.
	45.	Mahato, R. I. et al. (1997). "Cationic Lipid-Based Gene Delivery Systems: Pharmaceutical Perspectives," <i>Pharm. Res.</i> 14(7):853-859.
	46.	Mangham D. C. et al. (1999). "A Novel Immunohistochemical Detection System Using Mirror Image Complementary Antibodies (MICA)," <i>Histopathology</i> 35(2):129-133.
	47.	Porath, J. et al. (1975). "Biospecific Affinity Chromatography and Related Methods," Chapter 2 <i>In The Proteins</i> , 3 rd edition, Neurath, H. et al., eds. Academic Press, Volume 1 pp. 95-178.
	48.	Riechmann, L. et al. (1988). "Reshaping Human Antibodies for Therapy," <i>Nature</i> 332:323-327
	49.	Shaw, D. R et al (1987). "Characterization of a Mouse/Human Chimeric Monoclonal Antibody (17-1A) to a Colon Cancer Tumor-Associated Antigen," <i>J. Immunol.</i> 138:4534-4538.
	50.	Shen, W-C et al. (1981). "CIS-Aconityl Spacer Between Daunomycin and Macromolecular Carriers: A Model of Ph-Sensitive Linkage Releasing Drug From a Lysosomotropic Conjugate," <i>Biochem. Biophys Res. Commun</i> 102:1048-1054.
	51.	Stephan, J-P et al. (1999). "Distribution and Function of the Adhesion Molecule BEN During Rat Development," <i>Dev. Bio.</i> 212:264-277.
	52.	Stephan, J-P. et al. (1999). "Selective Cloning of Cell Surface Proteins Involved in Organ Development: Epithelial Glycoprotein Is Involved in Normal Epithelial Differentiation," <i>Endocrinology</i> 140(12):5841-5854.
	53.	Tempest, P. R. et al. (1991). "Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection <i>In Vivo</i> ," <i>BioTechnology</i> 9:266-271.
	54.	Trouet, A. et al. (1982). "A Covalent Linkage Between Daunorubicin and Proteins That is Stable in Serum and Reversible by Lysosomal Hydrolases, as Required for a Lysosomotropic Drug-Carrier Conjugate: <i>In Vitro</i> and <i>In Vivo</i> Studies," <i>Proc. Natl. Acad. Sci.</i> 79:626-629.
	55.	Verhoeven, M. et al. (1988). "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," <i>Science</i> 239:1534-1536.
✓	56.	Weimer, L. M. et al. (2001). "Therapeutic Monoclonal Antibodies: General Principles," Chapter 20, Section 5 <i>In Cancer: Principles and Practice of Oncology</i> , 6 th Edition, Freeman, Jr., Stuart, J. et al., eds, Lippincott Williams & Wilkins, pp. 495-508.

EXAMINER:

/Anne Holleran/ (06/22/2006)

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 415072002300

Application Number 10/713,248

Applicant

Jennie P. MATHER et al.

Filing Date November 13, 2003

Group Art Unit Not Yet Assigned

Mailing Date February 23, 2004

ALH

- | | |
|-----|--|
| 57. | Wheatley, S. P. et al. (1998). "Indirect Immunofluorescence Microscopy in Cultured Cells," Chapter 18 <i>In Animal Cell Culture Methods</i> , Mather, J.P. and Barnes, eds, Academic Press, Inc. Vol 57, pp. 313-332. |
| 58. | Winter, G. et al. (1994). "Making Antibodies By Phage Display Technology," <i>Annual. Rev. Immunol.</i> 12:433-455. |
| 59. | Winter, G. et al. (1991). "Man-Made Antibodies," <i>Nature</i> 349:293-299. |
| 60. | Woodruff, T. K. (1998). "Cellular Localization of mRNA and Protein: <i>In Situ</i> Hybridization Histochemistry and <i>in Situ</i> Ligand Binding," Chapter 19 <i>In Animal Cell Culture Methods</i> , Mather, J.P. et al., eds, Academic Press, Inc. Vol 57, pp. 333-351. |
| 61. | Yang, H. M. et al. (1988). "Pharmacokinetics and Mechanism of Action of a Doxorubicin-Monoclonal Antibody 9.2.27 Conjugate Directed to a Human Melanoma Proteoglycan," <i>J. Natl. Can. Inst</i> 80:1154-1159. |

EXAMINER:

/Anne Holleran/ (06/22/2008)

CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



ALTERNATIVE TO PTO/5808a/b (06-03)

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/713,248		
		Filing Date	November 13, 2003		
		First Named Inventor	Jennie P. MATHER		
		Art Unit	1642 (647)		
		Examiner Name	A. Holleran		
Sheet	1	of	1	Attorney Docket Number	415072002300

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Y ³
		Country Code ⁴ -Number-Kind Code ² (if known)				
ALH	1.	WO-2004/043239-A2	05-27-2004	Raven biotechnologies, inc.		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			Y ³
ALH	2.	International Search Report issued July 12, 2005, for PCT Application No. PCT/US03/36134, filed November 13, 2003, 5 pages.			
ALH	3.	Smith, G.M. et al. (1997). "Detection of a Soluble Form of the Leukocyte Surface Antigen CD48 in Plasma and its Elevation in Patients with Lymphoid Leukemias and Arthritis," <i>Journal of Clinical Immunology</i> 17(6):502-509.			

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Anne Holleran/ (08/22/2006)
pa-995744	